The world's only formulation of long-acting goserelin microspheres approved for launch in China
The only new chemical entity approved by the FDA for the treatment of metastatic SCLC in the past 26 years
For the treatment of postmenopausal women with osteoporosis at high risk of fracture
Toludesvenlafaxine Hydrochloride Extended-Release Tablets, for treating Major Depressive Disorder (MDD)
Chemical sensitizer for cancer radiotherapy
Received marketing approval in China for the treatment of NSCLC, colorectal cancer, glioblastoma, ovarian cancer and cervical cancer.
Independently developed innovative microsphere formulation, for treatment of schizophrenia
Atypical anti-psychotic medicines with antidepressant properties
The paclitaxel liposome injection indicated for multiple cancers
The only Acarbose capsule in China managing Type 2 diabetes adjunct to diet control
Xuezhikang—The evidence-based and internationally recognized Chinese lipid-adjusting drug
Received marketing approval in several European countries for the treatment of mild to moderate dementia associated with Alzheimer's disease
For treatment of cerebral edema, swelling caused by trauma or surgery and venous reflux disorders